Thiotepa in autologous stem cell transplantation (ASCT):A non-interventional, prospective study to assess safety and efficacy of Thiotepa-based high dose chemotherapy (HDCT) prior to autologous stem cell transplantation in adults with B- or T-cell lymphoma (non-Hodgkin lymphoma or Hodgkin lymphoma) with or without CNS involvement or with primary CNS lymphoma.
Recruiting
- Conditions
- B- or T-cell lymphoma (non-Hodgkin lymphoma or Hodgkin lymphoma) with or without CNS involvement or with primary CNS lymphomaC81C82C83C84C85Hodgkin lymphomaFollicular lymphomaNon-follicular lymphomaMature T/NK-cell lymphomas
- Registration Number
- DRKS00005719
- Lead Sponsor
- RIEMSER Pharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
signed informed consent form
- age = 18 years
- patients with a documented B- or T-cell lymphoma (non-Hodgkin lymphoma or Hodgkin lymphoma) with or without CNS involvement or with primary CNS lymphoma
- first autologous stem cell transplantation (ASCT)
- Thiotepa-based high dose chemotherapy prior to ASCT
Exclusion Criteria
Contraindications:
Hypersensitivity to the active substance.
Pregnancy and lactation
Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method